Polypharmacy for schizophrenia

Current Opinion in Psychiatry

Volumn 26, Issue 2, 2013, Pages 208-213

  Ballon, Jacob ^a   Stroup, T Scott ^a  

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

Author keywords

pharmacoepidemiology; polypharmacy; randomized controlled trial; schizophrenia; treatment refractory

Indexed keywords

ARIPIPRAZOLE; BENZODIAZEPINE; CLOZAPINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; HALOPERIDOL; LAMOTRIGINE; METFORMIN; MIRTAZAPINE; OLANZAPINE; RITANSERIN; TOPIRAMATE; TRAZODONE; VALPROIC ACID; ZONISAMIDE;

CLINICAL EFFECTIVENESS; COGNITIVE DEFECT; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; MONOTHERAPY; MORTALITY; PHARMACOEPIDEMIOLOGY; POLYPHARMACY; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SUICIDE; TREATMENT RESPONSE; WEIGHT GAIN;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; HUMANS; POLYPHARMACY; SCHIZOPHRENIA;

EID: 84873412913     PISSN: 09517367     EISSN: 14736578     Source Type: Journal    
DOI: 10.1097/YCO.0b013e32835d9efb     Document Type: Review

References (140)

1. Lloyd K, White J. Democratizing clinical research. Nature 2011; 474:277- 278
2. Leucht S, Correll CU, Kane JM. Approaches to treatment-resistant patients, in schizophrenia. 3rd ed. In: Weinberger DR, Harrison PJ, editors. Oxford, UK: Wiley-Blackwell; 2011. pp. 540-560. doi:10.1002/9781444327298.ch26
3. Hert MD, van Winkel R, Wampers M, et al. Remission criteria for schizophrenia: Evaluation in a large naturalistic cohort. Schizophr Res 2007; 92:68-73 (Pubitemid 46561226)
4. Correll CU, Rummel-Kluge C, Corves C, et al. Antipsychotic combinations vs monotherapy in schizophrenia: A meta-analysis of randomized controlled trials. Schizophr Bull 2009; 35:443-457
5. Essock SM, Schooler NR, Stroup TS, et al. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry 2011; 168:702-708
6. Rothbard AB, Kuno E, Foley K. Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia. Schizophr Bull 2003; 29:531-540 (Pubitemid 37339387)
7. Krivoy A, Malka L, Fischel T, et al. Predictors of clozapine discontinuation in patients with schizophrenia. Int Clin Psychopharmacol 2011; 26:311-315
8. Cipriani A, Boso M, Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst Rev 2009:CD006324. doi: 10.1002/14651858.CD006324.pub2
9. Muscatello MR, Bruno A, Pandolfo G, et al. Effect of aripiprazole augmentation of clozapine in schizophrenia: A double-blind, placebo-controlled study. Schizophr Res 2011; 127:93-99
10. Mico U, Bruno A, Pandolfo G, et al. Duloxetine as adjunctive treatment to clozapine in patients with schizophrenia: A randomized, placebo-controlled trial. Int Clin Psychopharmacol 2011; 26:303-310
11. Muscatello MR, Bruno A, Pandolfo G, et al. Topiramate augmentation of clozapine in schizophrenia: A double-blind, placebo-controlled study. J Psychopharmacol 2011; 25:667-674
12. Whitehead C, Moss S, Cardno A, Lewis G. Antidepressants for people with both schizophrenia and depression. Cochrane Database Syst Rev 2002:CD002305
13. Rummel C, Kissling W, Leucht S. Antidepressants for the negative symptoms of schizophrenia. Cochrane Database Syst Rev 2006: CD005581
14. Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010; 36:71-93
15. Volz A, Khorsand V, Gillies D, Leucht S. Benzodiazepines for schizophrenia. Cochrane Database Syst Rev 2007:CD006391
16. Schwarz C, Volz A, Li C, Leucht S. Valproate for schizophrenia. Cochrane Database Syst Rev 2008:CD004028
17. Premkumar TS, Pick J. Lamotrigine for schizophrenia. Cochrane Database Syst Rev 2006: CD005962
18. Leucht S, Kissling W, McGrath J, White P. Carbamazepine for schizophrenia. Cochrane Database Syst Rev 2007:CD001258
19. Leucht S, Kissling W, McGrath J. Lithium for schizophrenia. Cochrane Database Syst Rev 2007:CD003834
20. Singh SP, Singh V, Kar N, Chan K. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: Meta-analysis. Br J Psychiatry 2010; 197:174-179
21. Iancu I, Tschernihovsky E, Bodner E, et al. Escitalopram in the treatment of negative symptoms in patients with chronic schizophrenia: A randomized double-blind placebo-controlled trial. Psychiatry Res 2010; 179:19-23
22. Cho SJ, Yook K, Kim B, et al. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: A randomized controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35:208-211
23. Tiihonen J, Suokas JT, Suvisaari JM, et al. Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry 2012; 69:476-483
24. Wu C-S, Lin Y-J, Liu S-K. Benzodiazepine use among patients with schizophrenia in Taiwan: A nationwide population-based survey. Psychiatric Serv 2011; 62:908-914
25. Bocquier A, Bezzou K, Nauleau S, Verger P. Dispensing of anxiolytics and hypnotics in southeastern France: Demographic factors and determinants of geographic variations. Fundament Clin Pharmacol 2008; 22:323-333 (Pubitemid 351712898)
26. Casey DE, Daniel DG, Wassef AA, et al. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 2003; 28:182-192
27. Porcelli S, Balzarro B, Serretti A. Clozapine resistance: Augmentation strategies. Eur Neuropsychopharmacol 2012; 22:165-182
28. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209- 1223 (Pubitemid 41345943)
29. Misawa F, Shimizu K, Fujii Y, et al. Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects? A crosssectional study. BMC Psychiatry 2011; 11:118
30. Gallego JA, Nielsen J, De Hert M, et al. Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf 2012; 11:527-542
31. Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand 2002; 106:323-330 (Pubitemid 35176874)
32. Simon V, van Winkel R, De Hert M. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry 2009; 70:1041-1050
33. Fleischhacker WW, Heikkinen ME, Olie JP, et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: A randomized, double-blind, placebocontrolled trial. Int J Neuropsychopharmacol 2010; 13:1115-1125
34. Barbui C, Accordini S, Nose M, et al. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: A randomized, controlled trial. J Clin Psychopharmacol 2011; 31:266-273
35. Tchoukhine E, Takala P, Hakko H, et al. Orlistat in clozapine- or olanzapinetreated patients with overweight or obesity: A 16-week open-label extension phase and both phases of a randomized controlled trial. J Clin Psychiatry 2011; 72:326-330
36. Henderson DC, Fan X, Copeland PM, et al. A double-blind, placebocontrolled trial of sibutramine for clozapine-associated weight gain. Acta Psychiatr Scand 2007; 115:101-105 (Pubitemid 46114870)
37. Narula PK, Rehan HS, Unni KES, Gupta N. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: A double-blind, placebo-controlled trial. Schizophr Res 2010; 118 (1-3): 218-223
38. McElroy SL, Winstanley E, Mori N, et al. A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain. J Clin Psychopharmacol 2012; 32:165-172
39. Lieberman J, Jarskog LF, Hamer R, et al. Metformin for obesity and metabolic abnormalities in schizophrenia. In: American College of Neuropsychopharmacology 49th Annual Meeting. Miami Beach, Florida; 2010
40. Praharaj SK, Jana AK, Goyal N, Sinha VK. Metformin for olanzapine-induced weight gain: A systematic review and meta-analysis. Br J Clin Pharmacol 2011; 71:377-382.
41. Kupfer DJ, First MB, Regier DA, editors. A research agenda for DSM-V. Washington, DC: American Psychiatric Association Press; 2002
42. Phillips J, Frances A, Cerullo MA, et al. The six most essential questions in psychiatric diagnosis: A pluralogue. Part 1: Conceptual and definitional issues in psychiatric diagnosis. Philos Ethics Humanit Med 2012; 7:3
43. Phillips J, Frances A, Cerullo MA, et al. The six most essential questions in psychiatric diagnosis: A pluralogue. Part 2: Issues of conservatism and pragmatism in psychiatric diagnosis. Philos Ethics Humanit Med 2012; 7:8
44. Phillips J, Frances A, Cerullo MA, et al. The six most essential questions in psychiatric diagnosis: A pluralogue. Part 3: Issues of utility and alternative approaches in psychiatric diagnosis. Philos Ethics Humanit Med 2012; 7:9
45. Phillips J, Frances A, Cerullo MA, et al. The Six Most Essential Questions in Psychiatric Diagnosis: A Pluralogue. Part 4: Conclusion. Philos Ethics Humanit Med 2012; 7
46. Carpenter WT, van Os J. Should attenuated psychosis syndrome be a DSM-5 diagnosis? Am J Psychiatry 2011; 168:460-463
47. Addington J, Cornblatt B, Cadenhead K, et al. At clinical high risk for psychosis: Outcome for nonconverters. Am J Psychiatry 2011; 168:800-805
48. Simon A, Velthorst E, Nieman D, et al. Ultra high-risk state for psychosis and nontransition: A systematic review. Schizophr Res 2011; 132:8-17
49. Fusar-Poli P, Bonoldi I, Yung A, et al. Predicting psychosis: Meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry 2012; 69:220-229
50. Yung A, Pan Yuen H, Berger G, Francey S. Declining transition rate in ultra high risk (prodromal) services: Dilution or reduction of risk? Schizophr Bull 2007; 33:673-681 (Pubitemid 47343718)
51. Cechnicki A, Hanuszklewicz I, Polczyk R, Blelanska A. Prognostic value of duration of untreated psychosis in long-term outcome of schizophrenia. Med Sci Monitor 2011; 17:277-283
52. Yap H. Early psychosis intervention. Singapore Med J 2010; 51:689- 693
53. Chuma J, Mahadun P. Predicting the development of schizophrenia in highrisk populations: Systematic review of the predictive validity of prodromal criteria. Br J Psychiatry 2011; 199:361-366
54. Nelson B, Yuen K, Yung A. Ultra high risk (UHR) for psychosis criteria: Are there different levels of risk for transition to psychosis? Schizophrenia Res 2011; 125:62-68
55. Fusar-Poli P, McGuire S, Borgwardt T. Mapping prodromal psychosis: A critical review of neuroimaging studies. Eur Psychiatry 2012; 27:181-191
56. Fusar-Poli P. Predictive power of attenuated psychosis syndrome: Is it really low? The case of mild cognitive impairment. Schizophrenia Res 2012; 135:192-193
57. Mechelli A, Riecher-Rossler A, Meisenzahl E, et al. Neuroanatomical abnormalities that predate the onset of psychosis. Arch Gen Psychiatry 2011; 68:489-495
58. Carrion R, Goldberg T,McLaughlin D, et al. Impact of neurocognition on social and role functioning in individuals at clinical high risk for psychosis. Am J Psychiatry 2011; 168:806-813
59. Keshavan M, De Lisi L, Seidman L. Early and broadly defined psychosis risk mental states. Schizophr Res 2011; 126:1-10
60. McGorry P, Pelosi A. Is early intervention in the major psychiatric disorders justified? BMJ 2009; 338:801-803
61. Marshall C, Addington J, Epstein I, et al. Treating young individuals at clinical high risk for psychosis. Early Interv Psychiatry 2012; 6:60-68
62. Morrison A, French P, Stewart S, et al. Early detection and intervention evaluation for people at risk of psychosis: Multisite randomised controlled trial. BMJ 2012; 344:1-14
63. Wood S, Yung A, McGorry P, Pantelis C. Neuroimaging and treatment evidence for clinical staging in psychotic disorders: From the at-risk mental state to chronic schizophrenia. Biol Psychiatry 2011; 70:619-625
64. McGorry P. Preemptive intervention in psychosis: Agnostic rather than diagnostic. Aust N Z J Psychiatry 2011; 45:515-519
65. McGorry P. Truth and reality in early intervention. Aust N Z J Psychiatry 2012; 46:313-317
66. Rosenman S, Anderson P. Does prodromal diagnosis delay early intervention? Aust N Z J Psychiatry 2011; 45:504-509
67. Tandon N, Montrose D, Shah J, et al. Early prodromal symptoms can predict future psychosis in familial high-risk youth. J Psychiatr Res 2012; 46:105- 110
68. Rossler W, Hengartner M, Ajdacic-Gross V, Haker H. Sub-clinical psychosis symptoms in young adults are risk factors for subsequent common mental disorders. Schizophr Res 2011; 131:18-23
69. Rietdijk J, Linszen D, van der Gaag M. Field testing attenuated psychosis syndrome criteria. Am J Psychiatry 2011; 168:1221
70. Woods S, Walsh B, Saksa J, McGlashan T. The case for including attenuated psychotic symptoms syndrome in DSM-5 as a psychosis risk syndrome. Schizophr Res 2010; 123:199-207
71. Fusar-Poli P, Yung A. Should attenuated psychosis syndrome be included in DSM-5? Lancet 2012; 379:591-592
72. Shrivastava A, McGorry PD, Tsuang M, et al. Attenuated psychotic symptoms syndrome as a risk syndrome of psychosis, diagnosis in DSM-V: The debate. Indian J Psychiatry 2011; 53:57-65
73. Carpenter WT, Van Os J. Response to Rietdijk et al. letter. Am J Psychiatry 2011; 168:1221.
74. Hollis C. Adult outcome of child- and adolescent-onset schizophrenia: Diagnostic stability and predictive validity. Am J Psychiatry 2000; 157: 1652-1659
75. Castro-Fornieles J, Parellada M, Gonzalez-Pinto A, et al. The child and adolescent first-episode psychosis study (CAFEPS): Design and baseline results. Schizophr Res 2007; 91:226-237 (Pubitemid 46343653)
76. Schimmelmann BG, Conus P, Edwards J, et al. Diagnostic stability 18 months after treatment initiation for first-episode psychosis. J Clin Psychiatry 2005; 66:1239-1246 (Pubitemid 41546503)
77. Correll CU, Lencz T, Smith CW, et al. Prospective study of adolescents with subsyndromal psychosis: Characteristics and outcome. J Child Adolesc Psychopharmacol 2005; 15:418-433 (Pubitemid 41192829)
78. Kumra S, Oberstar JV, Sikich L, et al. Efficacy and tolerability of secondgeneration antipsychotics in children and adolescents with schizophrenia. Schizophr Bull 2008; 34:60-71 (Pubitemid 350262286)
79. Häfner H, Maurer K, Löffler W. Onset and early course of schizophrenia. In: Häfner H, Gattez WF, editors. Search for the causes of schizophrenia. 3rd ed. Berlin, Heidelberg: Springer; 1995. pp. 43-66
80. Hans SL, Auerbach JG, Arsanow JR, et al. Social adjustment of adolescents at risk for schizophrenia: The Jerusalem Infant Development Study. J Am Acad Child Adolesc Psychiatry 2000; 39:1406-1414
81. Joa I, Johannessen JO, Langeveld J, et al. Baseline profiles of adolescent vs. adult-onset first-episode psychosis in an early detection program. Acta Psychiatr Scand 2009; 119:494-500
82. Ballageer T, Malla A, Manchanda R, et al. Is adult-onset first-episode psychosis different from adult onset? J Am Acad Child Adolesc Psychiatry 2005; 44:782-789 (Pubitemid 41026282)
83. Basso MR, Nasrallah HA, Olson SC, et al. Cognitive deficits distinguish patients with adolescent- and adult-onset schizophrenia. Neuropsychiatry Neuropsychol Behav Neurol 1997; 10:107-112 (Pubitemid 27211965)
84. Vyas NS, Patel NH, Puri BK. Neurobiology and phenotypic expression in early onset schizophrenia. Early Interv Psychiatry 2011; 5:3-14
85. Reichert A, Kreiker S, Mehler-Wex C, Warnke A. The psychopathological and psychosocial outcome of early-onset schizophrenia: preliminary data of a 13-year follow-up. Child Adolesc Psychiatry Ment Health 2008; 2:6
86. Amminger GP, Henry LP, Harrigan SM, et al. Outcome in early-onset schizophrenia revisited: Findings from the Early Psychosis Prevention and Intervention Centre long-term follow-up study. Schizophr Res 2011; 131:112-119
87. Schimmelmann BG, Conus P, Cotton S, et al. Pretreatment, baseline, and outcome differences between early-onset and adult-onset psychosis in an epidemiological cohort of 636 first-episode patients. Schizophr Res 2007; 95:1-8 (Pubitemid 47315740)
88. Schimmelmann BG, Huber CG, Lambert M, et al. Impact of duration of untreated psychosis on pretreatment, baseline, and outcome characteristics in an epidemiological first-episode psychosis cohort. J Psychiatr Res 2008; 42:982-990
89. Ueland T, Rund BR. A controlled randomized treatment study: The effects of a cognitive remediation program on adolescents with early onset psychosis. Acta Psychiatr Scand 2004; 109:70-74 (Pubitemid 38161103)
90. Ueland T, Rund BR. Cognitive remediation for adolescents with early onset psychosis: A 1-year follow-up study. Acta Psychiatr Scand 2005; 111:193- 201 (Pubitemid 40342187)
91. Wykes T, Newton E, Landau S, et al. Cognitive remediation therapy (CRT) for young early onset patients with schizophrenia: An exploratory randomized controlled trial. Schizophr Res 2007; 94:221-230 (Pubitemid 47031576)
92. Urben S, Pihet S, Jaugey L, et al. Computer-assisted cognitive remediation in adolescents with psychosis or at risk for psychosis: A 6-month follow-up. Acta Neuropsychiatrica 2012; 24:328-335
93. Jenner JA, van de Willige G. HIT, hallucination focused integrative treatment as early intervention in psychotic adolescents with auditory hallucinations: A pilot study. Acta Psychiatr Scand 2001; 103:148-152 (Pubitemid 32147136)
94. Wragg JA, Whitehead RE. CBT for adolescents with psychosis: Investigating the feasibility and effectiveness of early intervention using a single case design. Behav Cogn Psychother 2004; 32:313-329 (Pubitemid 38931726)
95. Bechdolf A, Tecic T, Lehnkuhl G, et al. Cognitive behavior therapy in adolescents with persistent symptoms. Results of a randomized trial. Eur Arch Psychiatry Clin Neurosci 2011; 261 (Suppl. 1):7-101
96. Rund BR, Meo L, Sollien T, et al. The Psychosis Project: Outcome and costeffectiveness of a psychoeducational treatment programme for schizophrenic adolescents. Acta Psychiatr Scand 1994; 89:211-218 (Pubitemid 24074838)
97. Jackson HJ, McGorry PD, Killackey E, et al. Acute-phase and 1-year follow-up results of a randomized controlled trial of CBT versus Befriending for firstepisode psychosis: The ACE project. Psychol Med 2008; 38:725-735 (Pubitemid 351483239)
98. Power PJ, Bell RJ, Mills R, et al. Suicide prevention in first episode psychosis: The development of a randomised controlled trial of cognitive therapy for acutely suicidal patients with early psychosis. Aust N Z J Psychiatry 2003; 37:414-420 (Pubitemid 37121574)
99. Jones C, Hacker D, Cormac I, et al. Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia [review]. Cochrane Database Syst Rev 2012; 4:CD008712
100. Linszen D, Dingemans P, Lenior ME. Early intervention and a five-year followup in young adults with a short duration of untreated psychosis: Ethical implications. Schizophr Res 2001; 51:55-61 (Pubitemid 32722069)
101. Zhang M, Wang M, Li J, et al. Randomised-control trial of family intervention for 78 first-episode male schizophrenic patients: An 18-month study in Suzhou, Jiangsu. Brit J Psychiatry 1994; 165:96-102 (Pubitemid 24259374)
102. Bird V, Premkumar P, Kendall T, et al. Early intervention services, cognitive behavioural therapy and family intervention in early psychosis: A systematic review. Brit J Psychiatry 2010; 197:350-356
103. Findling RL, Robb A, Nyilas M, et al. A multiple-center, randomized doubleblind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 2008; 165:1432-1441
104. Kryzhanovskaya L, Schulz C, McDougle C, et al. Olanzapine vs. placebo in adolescents with schizophrenia: A 6-week, randomized, double-blind, placebo- controlled trial. J Am Acad Child Adolesc Psychiatry 2009; 48:60-70
105. Singh J, Robb A, Vijapurkar U, et al. A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents. Biol Psychiatry 2011; 70:1179-1187
106. Findling RL, Mckenna K, Earley WR, et al. Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, randomized, placebo-controlled trial. J Child Adolesc Psychopharmacol 2012; 22:327-342
107. Haas M, Unis AS, Armenteros J, et al. A 6-week, randomized double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol 2009; 19:611-621
108. Haas M, Eerdekens M, Kushner S, et al. Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: Double-blind study. Br J Psychiatry 2009; 194:158-164
109. Findling RL, Cavusz I, Pappadopulos E, et al. A placebo-controlled trial to evaluate the efficacy and safety of flexibly dosed oral ziprasidone in adolescent subjects with schizophrenia. Schizophr Res 2012; 117:437
110. Correll CU, Kratochvil CJ, March J. Developments in pediatric psychopharmacology: Focus on stimulants, antidepressants and ntipsychotics. J Clin Psychiatry 2011; 72:655-670
111. Sikich L, Hamer RM, Bashford RA, et al. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: A double-blind, randomized, 8-week trial. Neuropsychopharmacology 2004; 29:133-145 (Pubitemid 38068023)
112. Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of firstand second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: Findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 2008; 165:1420-1431
113. Arango C, Robles O, Parellada M, et al. Olanzapine compared to quetiapine in adolescents with a first psychotic episode. Eur Child Adolesc Psychiatry 2009; 18:418-428
114. Jensen JB, Kumra S, Leitten W, et al. A comparative pilot study of secondgeneration antipsychotics in children and adolescents with schizophreniaspectrum disorder. J Child Adolesc Psychopharmacol 2008; 18:317-326
115. Kumra S, Frazier JA, Jacobsen LK, et al. Childhood-onset schizophrenia: A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 1996; 53:1090-1097 (Pubitemid 26422059)
116. Shaw P, Sporn A, Gogtay N, et al. Childhood-onset schizophrenia: A doubleblind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry 2006; 63:721-730
117. Kumra S, Kranzler H, Gerbino-Rosen G, et al. Clozapine and 'high-dose' olanzapine in refractory early-onset schizophrenia: A 12-week randomized and double-blind comparison. Biol Psychiatry 2008; 63:524-529 (Pubitemid 351220784)
118. Correll CU. Antipsychotic medications: Typical and atypical. In: Martin A, Scahill L, Kratochvil CJ, editors. Pediatric sychopharmacology: Rinciples and practice. 2nd ed. New York: Oxford University Press; 2011. pp. 312- 337
119. Correll CU, Kane JM. One-year tardive dyskinesia rates in children and adolescents treated with second-generation antipsychotics. A systematic review. J Child Adolesc Psychopharmacol 2007; 17:647-655 (Pubitemid 350058977)
120. Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of secondgeneration antipsychotic medications during first-time use in children and adolescents. JAMA 2009; 302:1765-1773
121. Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 2006; 45:771-791 (Pubitemid 43932904)
122. Kryzhanovskaya LA, Xu W, Millen BA, et al. Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine. J Child Adolesc Psychopharmacol 2012; 22:157-165
123. De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2011; 8:114-126
124. De Hert M, Dobbelaere M, Sheridan EM, et al. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry 2011; 26:144-158
125. Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. Trends Mol Med 2011; 17:97-107
126. Correll CU. From receptor pharmacology to improved outcomes: Individualizing the selection, dosing, and switching of antipsychotics. Eur Psychiatry 2010; 25:12-21
127. Correll CU. Antipsychotic use in children and adolescents: Minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry 2008; 47:9-20
128. Barnes TRE. Abnormal involuntary movement scale. A rating scale for druginduced akathisia. Br J Psychiatry 1989; 154:672-676
129. Guy WA. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Department of Health Education and Welfare; 1976. pp. 534-537
130. Simpson GM, Angus JWS. A rating scale for extra-pyramidal side effects. Acta Psychiatr Scand 1970; 212:44-51
131. Manu P, Correll CU, Wampers M, et al. Prediabetic increase in haemoglobin A1c compared with impaired fasting glucose in patients receiving antipsychotic drugs. Eur Neuropsychopharmacol 2012. [Epub ahead of print]
132. Ho J, Panagiotopoulos C, McCrindle B, et al. Management recommendations for metabolic complications associated with second generation antipsychotic use in children and youth. J Can Acad Child Adolesc Psychiatry 2011; 20:234-241
133. Schimmelmann BG, Paulus S, Schacht M, et al. Subjective distress related to side effects and subjective well being in first admitted adolescents with early onset psychosis treated with atypical antipsychotics. J Child Adolesc Psychopharmacol 2005; 15:249-258 (Pubitemid 40734104)
134. Kishimoto T, de Hert M, Carlson HE, et al. Osteoporosis and fracture risk in people with schizophrenia. Curr Opin Psychiatry 2012; 25:415-429
135. Caemmerer J, Correll CU, Maayan L. Acute and maintenance effects of nonpharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: A meta-analytic comparison of randomized controlled trials. Schizophr Res 2012; 140:159-168
136. Lehman AF, Kreyenbuhl J, Buchanan RW, et al. The Schizophrenia Patient Outcomes Research Team (PORT): Updated treatment recommendations 2003. Schizophr Bull 2004; 30:193-217
137. De Hert M, van Winkel R, Wampers M, et al. Remission criteria for schizophrenia: Evaluation in a large naturalistic cohort. Schizophr Res 2007; 92:68-73 (Pubitemid 46561226)
138. National Institute for Health and Clinical Excellence. NICE Clinical Guideline 82: Schizophrenia: Core interventions in the treatment and management of schizophrenia in adults in primary and secondary care, 2009. http://publications.nice.org.uk/schizophrenia-cg82. [Accessed 18 December 2012]
139. Leucht S, Correll CU, Kane JM. Approaches to treatment resistant patients. In: Hirsch SR, Weinberger DR, editors. Schizophrenia. 3rd ed. West Sussex: Blackwell Publishing Ltd; 2011. pp. 540-560
140. Lambert M, Bock T, Schöttle D, et al. Assertive Community Treatment (ACT) as part of integrated care vs. standard care: A 12-month trial in patients with first- and multiple-episode schizophrenia spectrum disorders treated with quetiapine immediate release (ACCESS trial). J Clin Psychiatry 2010; 71:1313-1323.